BioMarin Pharmaceutical Hits Day High with 7.77% Surge in Stock Price

BioMarin Pharmaceutical, Inc. has experienced a notable uptick in its stock performance today, gaining 7.77% as of May 21, 2026. The stock reached an intraday high of USD 54.45, reflecting a significant movement within the small-cap pharmaceuticals and biotechnology sector. In terms of performance metrics, BioMarin's one-day gain stands in stark contrast to the S&P 500, which only saw a modest increase of 0.17%. Over the past week, BioMarin has also outperformed the benchmark, rising 1.62% compared to the S&P 500's decline of 0.74%. However, the stock has faced challenges over longer periods, with a year-to-date performance of -8.97% and a three-year performance of -41.13%, indicating a consistent underperformance against the broader market. Financially, BioMarin has shown resilience with a robust operating profit growth rate of 60.52% annually and a significant increase in net profit, which has grown by 90.44%. The company maintains a healthy operating cash flow of USD 913.97 million, while raw material costs have decreased by 10.47% year-over-year. Despite these positive indicators, the stock trades at a premium valuation with a Price to Book ratio of 1.82, reflecting its high institutional holdings and the complexities of its market position.